With weight loss drugs taking the world by storm, more people are exploring adding these medical marvels to their toolkits. Aside from the impressive results, GLP-1s seem to be increasingly easy for ...

In December, Novo Nordisk announced that the Food and Drug Administration had approved its once-daily Wegovy pill, the first oral GLP-1 medicine for obesity in the United States. It remains the only ...

Clinical trials show retatrutide, Eli Lilly's new triple-agonist drug, delivered 24.2% weight loss in 48 weeks and the ...

CNBC spoke to executives from Eli Lilly, Novo Nordisk, Pfizer and other drugmakers at the annual JPMorgan Healthcare ...

The GLP-1 moment signals how quickly a high-demand therapy can upend established care patterns—and how similar innovations ...

New weight-loss drugs in the works will offer more choices beyond GLP-1 options Wegovy and Zepbound. What to know about ...

Welcome to The Thin Line, The New York Post’s new series about the darker side of GLP-1 drugs. Though GLP-1 agonists sold ...

As many as 12% of Americans are currently using GLP-1 medications such as Ozempic and Wegovy, according to one estimate.

GLP‑1 weight‑loss drugs are reshaping food industry demand, but side effects, cost barriers and unclear long‑term impacts ...

At a high level these drugs mimic glucagon-like peptide-1, or GLP-1, a hormone our bodies naturally produce in the gut. When ...

As the GLP-1 trend expands, a 'halo effect' is developing. Consumers in families of GLP-1 users are increasingly eating GLP-1 ...

Retailer offerings trumpet a variety of claims about protein, fat and fibre levels, while some seem to simply be smaller ...